Therefore, YTHDF1 deficiency in DCs enhances antitumor immunity by promoting the cross-presentation of tumor antigens and cross-priming of CD8+ T cells, indicating that YTHDF1 is likely to become a promising antitumor target (Karthiya and Khandelia, 2020). This evidence concerns the gene YTHDF1 and neoplasm.